We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
Read MoreHide Full Article
Shares of TherapeuticsMD, Inc. (TXMD - Free Report) were up 4.4% in after-market trading on Dec 28, following the submission of a new drug application (“NDA”) to the FDA for pipeline candidate, TX-001HR.
In fact, TherapeuticsMD’s share price has increased 12.5% in the past six months, outperforming the industry’s gain of 5.4%.
The NDA includes data from successfully completed pivotal phase III Replenish study. The study evaluated TX-001HR, a bio-identical hormone therapy combination of estradiol and progesterone, in post-menopausal women who suffer from moderate-to-severe vasomotor symptoms (“VMS”).
Data from the study showed that TX-001HR achieved statistically significant and clinically meaningful reduction in frequency and severity of VMS (hot flashes) from baseline compared to placebo.
TX-001HR is the first investigational bio-identical combination hormone therapy of estradiol and progesterone. The company believes there is significant demand for a bio-identical hormone therapy for treating VMS, which is currently being treated with unapproved combinations made by independent and community pharmacies.
A potential approval to TX-001HR will help patients to use proven safe and effective treatment and the cost may also get reimbursed through insurance.
The company expects a decision from the FDA on the acceptance of the NDA by March 2018.
We remind investors that last week, the FDA also accepted TherapeuticsMD’s resubmission of the NDA for TX-004HR seeking approval to treat dyspareunia. A decision is expected in May 2018.
The company currently earns from manufacture and distribution of branded and generic prescription prenatal vitamins. Approval of the NDAs will likely boost the company’s revenues.
Celldex’s loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents in the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA’s loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 in the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%. The company’s shares have returned 5.7% so far this year. The stock is up 8.1% so far this year.
Corcept’s earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The stock is up 150.2% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
Shares of TherapeuticsMD, Inc. (TXMD - Free Report) were up 4.4% in after-market trading on Dec 28, following the submission of a new drug application (“NDA”) to the FDA for pipeline candidate, TX-001HR.
In fact, TherapeuticsMD’s share price has increased 12.5% in the past six months, outperforming the industry’s gain of 5.4%.
The NDA includes data from successfully completed pivotal phase III Replenish study. The study evaluated TX-001HR, a bio-identical hormone therapy combination of estradiol and progesterone, in post-menopausal women who suffer from moderate-to-severe vasomotor symptoms (“VMS”).
Data from the study showed that TX-001HR achieved statistically significant and clinically meaningful reduction in frequency and severity of VMS (hot flashes) from baseline compared to placebo.
TX-001HR is the first investigational bio-identical combination hormone therapy of estradiol and progesterone. The company believes there is significant demand for a bio-identical hormone therapy for treating VMS, which is currently being treated with unapproved combinations made by independent and community pharmacies.
A potential approval to TX-001HR will help patients to use proven safe and effective treatment and the cost may also get reimbursed through insurance.
The company expects a decision from the FDA on the acceptance of the NDA by March 2018.
We remind investors that last week, the FDA also accepted TherapeuticsMD’s resubmission of the NDA for TX-004HR seeking approval to treat dyspareunia. A decision is expected in May 2018.
The company currently earns from manufacture and distribution of branded and generic prescription prenatal vitamins. Approval of the NDAs will likely boost the company’s revenues.
TherapeuticsMD, Inc. Price
TherapeuticsMD, Inc. Price | TherapeuticsMD, Inc. Quote
Zacks Rank & Stocks to Consider
TherapeuticsMD carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. (CLDX - Free Report) , ACADIA Pharmaceuticals Inc. (ACAD - Free Report) and Corcept Therapeutics Inc. (CORT - Free Report) . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Celldex’s loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents in the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA’s loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 in the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%. The company’s shares have returned 5.7% so far this year. The stock is up 8.1% so far this year.
Corcept’s earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The stock is up 150.2% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>